Production (Stage)
Lotus Bio-Technology Development Corp.
LBTD
$0.00
$0.000.00%
OTC PK
| 12/31/2017 | 09/30/2017 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -96.08% | 15,200.00% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -96.08% | 15,200.00% | |||
| Operating Income | 96.08% | -15,200.00% | |||
| Income Before Tax | 96.08% | -15,200.00% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 96.08% | -15,200.00% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 96.08% | -15,200.00% | |||
| EBIT | 96.08% | -15,200.00% | |||
| EBITDA | -- | -- | |||
| EPS Basic | 100.00% | -- | |||
| Normalized Basic EPS | 100.00% | -- | |||
| EPS Diluted | 100.00% | -- | |||
| Normalized Diluted EPS | 100.00% | -- | |||
| Average Basic Shares Outstanding | 153.94% | 59.09% | |||
| Average Diluted Shares Outstanding | 153.94% | 59.09% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||